All | PCMH Pilot Practices Removed | |||
---|---|---|---|---|
OR* | 95% CI | OR* | 95% CI | |
Diabetes (only) | ||||
Diabetes-specific medications† | ||||
Non-PCIP | 1.14 | 0.81–1.60 | 1.12 | 0.79–1.58 |
PCIP | 2.03‡ | 1.08–3.83 | 1.76 | 0.96–3.24 |
Lipid-controlling medications§ | ||||
Non-PCIP | 0.85 | 0.55–1.32 | 0.83 | 0.53–1.29 |
PCIP | 1.64 | 0.73–3.65 | 1.59 | 0.73–3.44 |
Hypertension (only) | ||||
Hypertension-specific medications‖ | ||||
Non-PCIP | 1.26‡ | 1.15–1.38 | 1.26‡ | 1.15–1.38 |
PCIP | 1.24‡ | 1.03–1.49 | 1.24‡ | 1.03–1.48 |
Lipid-controlling medications§ | ||||
Non-PCIP | 1.28‡ | 1.13–1.44 | 1.28‡ | 1.13–1.49 |
PCIP | 1.11 | 0.86–1.44 | 1.16 | 0.90–1.50 |
Comorbid diabetes and hypertension | ||||
Diabetes-specific medications† | ||||
Non-PCIP | 1.03 | 0.90–1.18 | 1.05 | 0.92–1.21 |
PCIP | 1.06 | 0.81–1.40 | 1.14 | 0.88–1.49 |
Hypertension-specific medications‖ | ||||
Non-PCIP | 1.19‡ | 1.04–1.36 | 1.19‡ | 1.04–1.36 |
PCIP | 1.10 | 0.84–1.44 | 1.10 | 0.85–1.43 |
Lipid-controlling medications§ | ||||
Non-PCIP | 1.14 | 0.99–1.32 | 1.16 | 1.00–1.33 |
PCIP | 1.26 | 0.93–1.72 | 1.25 | 0.94–1.68 |
↵* Odd ratios (OR) shown for changes in the odds of the proportion of members who are adherent (i.e., medication possession ratio ≥80%) from baseline to the end of the study.
↵† Diabetes therapeutic drug classes include biguanides, sulfonylureas, thiazolidinediones, insulins, dipeptidyl peptidase IV inhibitors.
↵‡ P values <.05.
↵§ Lipid-controlling therapeutic drug classes include HMG-CoA reductase inhibitors and fibric acid derivatives.
↵‖ Hypertension therapeutic drug classes include angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, beta-adrenergic blocking agents, calcium channel blocking agents (dihydropyridines), phosphodiesterase inhibitors, thiazide diruetics.
CI, confidence interval; PCMH, patient-centered medical home; OR, odds ratio; PCIP, Primary Care Information Project.